All In Biotech

Drug Trial Radar · NCT01429441

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Last checked: Nov 20, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Oct 2011

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
ThromboGenicsIndustry
Sponsor type
Industry
First posted
Sep 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.

Conditions

  • Vitreomacular Adhesion Including Macular Hole

Interventions

  • OcriplasminDrug

    0.125 mg single intravitreal injection

  • Sham injectionOther

    Sham injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28Time frame: Day 28

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Consultants of Arizona

    Phoenix, Arizona

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retina Consultants Medical Group

    Sacramento, California

  • West Coast Retina Group, Inc

    San Francisco, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • MedEye Associates

    Miami, Florida

  • Center for Retina and Macular Disease

    Winter Haven, Florida

  • Associated Retinal Consultants

    Royal Oak, Michigan

  • Sabates Eye Center Research

    Kansas City, Missouri

  • Eyesite Opthalmic Services, PA

    Portsmouth, New Hampshire

  • Retina-Vitreous Center, PA

    New Brunswick, New Jersey

  • Retina Association of NJ

    Teaneck, New Jersey

  • Retina Vitrous Surgeons of CNY

    Syracuse, New York

  • Southeast Clinical Research, PA

    Charlotte, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Retina Associates of Cleveland

    Cleveland, Ohio

  • Mid Atlantic Retina

    Huntingdon Valley, Pennsylvania

  • Texas Retina Associates

    Arlington, Texas

  • Retina Research Center

    Austin, Texas

  • Texas Retina Associates

    Dallas, Texas

  • Retina Consultants, PA

    Fort Worth, Texas

  • Vitroretinal Consultants

    Houston, Texas

  • Valley Retina Institute, P.A.

    McAllen, Texas

  • Retina Consultants of San Antonio

    San Antonio, Texas

  • Eye Care Associate

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.